What is it?

Glutathione is a small peptide composed of three amino acids (cysteine, glutamic acid and glycine) that is produced in greater amounts in the human liver and plays a key role in protecting cells against oxidative stress (internal and external), liver detoxification and maintenance of the immune system.

The absorption of glutathione orally is greatly reduced, so to obtain the best results, its administration should occur by blood.

The infusion we use contains Glutathione in its reduced form (GSH) and in the form of S-acetyl-glutathione (SAG – GSH precursor molecule). The unique combination of these two forms of Glutathione in the same infusion allows for a longer lasting and deeper effect.

soro glutatião detox fígado



Some of the most common uses of Glutathione:

  • Reduction of toxicity and side effects of chemotherapy.
  • Heavy metal detoxification
  • Liver detoxification
  • Hepatic steatosis (“fatty liver”)
  • Idiopathic pulmonary fibrosis / Cystic fibrosis
  • Contrast-induced nephropathy
  • Parkinson’s disease
  • Lowering blood pressure in diabetic patients
  • Improving male fertility
  • Liver carcinoma
  • Anemia
  • Increased energy
  • Slow-aging


Glutathione infusions are incorporated into our Immune Booster Program

Contact us and learn more!




Scientific references

  1. Pizzorno J. Glutathione!. Integr Med (Encinitas). 2014;13(1):8–12. [PubMed]
  2. Biswas SK, Rahman I. Environmental toxicity, redox signaling and lung inflammation: the role of glutathione. Mol Aspects Med. 2009 [PubMed]
  3. Marí M, Morales A, Colell A, García-Ruiz C, Fernández-Checa JC. Mitochondrial glutathione, a key survival antioxidant. Antioxid Signal Redox. 2009 [PubMed]
  4. Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson’s disease. Mov Disord. 2009 [PubMed]
  5. Aebi S, Assereto R, Lauterburg BH. High-dose intravenous glutathione in man. Pharmacokinetics and effects on cyst(e)ine in plasma and urine. Eur J Clin Invest. 1991 Feb [PubMed]
  6. Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G. Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 1996 Oct [PubMed]
  7. Johnson WM, Wilson-Delfosse AL, JJ Mieyal. Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients. 2012 Oct [PubMed]
  8. Chawla RK, Lewis FW, Kutner MH, Bate DM, Roy RG, Rudman D. Plasma cysteine, cystine, and glutathione in cirrhosis. Gastroenterology. 1984 Oct [PubMed]